Novo Nordisk expands research collaboration to develop hemophilia drug

Collaborations between Novo Nordisk and US-based biotech firm 2Seventy Bio, spun off from Bluebird Bio, have expanded to include the development of a treatment for bleeding disorder hemophilia A.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
by marketwire, translated by daniel pedersen

Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading